

# Advancing NIH Research on the Health of Women: A 2021 Conference

# A path forward towards accelerating cervical cancer eradication

Diana SM Buist, PhD, MPH Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute Professor, Kaiser Permanente Bernard J. Tyson School of Medicine

Affiliate Professor, University of Washington, School of Public Health, Departments of Epidemiology and Health Systems and Population Health



Facebook: /NIHORWH
Twitter: @NIH ORWH

www.nih.gov/women #ResearchForWomen

## **Disclosures**


- Funded by: NCI, AHRQ, PCORI and CDC
  - Co-I on Completed NCI trial: Home-Based Options to Make Cervical Cancer Screening Easy (HOME) trial NCT02005510 (R01 CA168598)


Clinical outcomes in underscreened females

 PI on NCI trial Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial (STEP) - NCT04679675 (R01 CA240375)

Screening uptake and completion by different outreach strategies stratified by screening history

Employed by Kaiser Foundation Health Plan of Washington





of women identified with cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).


Global strategy to accelerate the elimination of cervical cancer as a public health problem



Achieving the 90-70-90 targets by 2030 would result in over 62 million cervical cancer deaths averted by 2120.







# Cancer Prevention through Vaccination with Long Sojourn time

# US population of females aged 30-64

73,180,000


18,295,000


14,000

50%




#### Percent up-to-date with cervical cancer screening by insurance status in the US















		Mailed HPV Kit	<b>Usual Care</b>	RR (95% CI)
JAMA Netw Open 2019	Screening initiation	2646 (26.6%)	1917 (17.4%)	1.53 (1.45-1.61)
NCT02005510 (R01 CA168598)				
10	Screening completed	2618 (26.3%)	1917 (17.4%)	1.51 (1.43-1.60)






complete




#### Instructions for Your Cervical **Cancer Screening Kit**




Please do not use this kit if you are pregnant.









STEP 1

STEP 2

STEP 4

NCT02005510 (R01 CA168598) NCT04679675 (R01 CA240375)

JAMA Netw Open 2019

JOURNAL OF WOMEN'S HEALTH Volume 00, Number 00, 2018 © Mary Ann Liebert, Inc. DOI: 10.1089/jwh.2018.7070

## Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result



Jasmin A. Tiro, PhD,<sup>1</sup> Andrea C. Betts, MPH,<sup>1,2</sup> Kilian Kimbel, BA,<sup>3</sup> Diana S.M. Buist, PhD,<sup>3</sup> Constance Mao, MD,<sup>4</sup> Hongyuan Gao, MS,<sup>3</sup> Lisa Shulman, MSW,<sup>3</sup> Colin Malone, MPH,<sup>5</sup> Tara Beatty, MA,<sup>3</sup> John Lin, BA,<sup>6</sup> Chris Thayer, MD,<sup>7</sup> Diana L. Miglioretti, PhD,<sup>3,8</sup> and Rachel L. Winer, PhD<sup>3,5</sup>


# Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits

J Med Screen
2020, Vol. 27(3) 146–156
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0969141319885994
journals.sagepub.com/home/msc



Colin Malone<sup>1</sup>, Jasmin A Tiro<sup>2</sup>, Diana SM Buist<sup>3</sup>, Tara Beatty<sup>3</sup>, John Lin<sup>1</sup>, Kilian Kimbel<sup>3</sup>, Hongyuan Gao<sup>3</sup>, Chris Thayer<sup>4</sup>, Diana L Miglioretti<sup>3,5</sup> and Rachel L Winer<sup>1,3</sup>

NCT02005510 R01 CA168598 31,619 females ages 30-64 due for cervical cancer screening recruited over 14 months



open access to scientific and medical research



REVIEW

## Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer

Taja Lozar<sup>1-3</sup>
Rahul Nagvekar<sup>4</sup>
Charles Rohrer <sup>5</sup>
Racheal Shamiso Dube
Mandishora<sup>6,7</sup>
Urska Ivanus <sup>3,8,9</sup>
Megan Burke Fitzpatrick <sup>1,5</sup>

Comment on this paper

Relative Sensitivity of ID NOW and RT-PCR for Detection of SARS-CoV-2 in an Ambulatory Population: Clinical Evaluation, Systematic Review and Meta-analysis

Yuan-Po Tu, Jameel Iqbal, (D) Timothy O'Leary doi: https://doi.org/10.1101/2020.12.07.20245225

Now published in eLife doi: 10.7554/eLife.65726

#### Local community

Community level resources
Medical care offerings
Lay support networks
Private cancer organizations
Local hospital and cancer

Services

Market

Level of competition

Managed care penetration

Percent nonprofit

Specialty mix

Local professional norms

MD practice organizations

Use of guidelines

Practice patterns

#### Provider / team

Knowledge, communication skills

Perceived barriers, norms, test efficacy

Cultural competency

Staffing mix and turnover

Role definition


Teamwork

#### Individual patient

Biological factors Socio-demographics Insurance coverage Risk status Comorbidities

Knowledge, attitudes, beliefs Decision-making preferences

Psychological reaction/coping



#### National

Policy — Affordable Care Act, professional guidelines Structure — Financial, political

Culture - Expectations

#### <u>State</u>

Policy - Medicaid Structure - Provider Mix Culture - advocacy groups attitude/expectations

# Organization / practice setting

Leadership

Organizational structure, policies & incentives

Delivery system design

Clinical decision support

Clinical information systems

Patient education & navigation

#### Family / social supports

Family dynamics Friends, network support

Taplin et al CEBP 2012

### Recommendations

- Learn from COVID
  - ✓ Primary prevention & education: What has worked to address vaccine hesitancy, how have complex scientific concepts been relayed to the public
  - ✓ Self-collection: increase validation and implementation evaluations
  - ✓ Speed
- Multi-everything
  - ✓ Multi-level, multi-site, multi-modalities (mixed methods), multi-lingual & multi-cultural
- Invest in training for researchers to communicate to various stakeholders
- Reform NIH funding paradigm
  - ✓ Faster
  - ✓ Innovative funding mechanisms (e.g., UG3-UH3; NIDDK PAR-20-160)

